Is the reflux disease questionnaire useful for identifying GERD according to the Montreal definition?

BMC Gastroenterology

Manuel Díaz-Rubio³  Mercedes Muñoz⁴  Eduardo Sobreviela¹  Javier Zapardiel²  Marta Barceló³  Enrique Rey³ 

[1] Biometrics Department, Quintiles Iberia, Madrid, Spain;Microbiology, Infanta Elena Hospital, Madrid, Spain;Department of Digestive Diseases, San Carlos Clinical Hospital, Madrid Complutense University, Madrid 28040, Spain;Medical Department, AstraZeneca, Spain

关键词: Patient-reported outcomes;    Questionnaires;    Heartburn;    GERD;   

Others  :  856664
DOI  :  10.1186/1471-230X-14-17

 received in 2013-10-06, accepted in 2013-12-30,  发布年份 2014

【 摘 要 】

Background

Scales for aiding physicians diagnose gastro-oesophageal reflux disease (GERD) have not been evaluated in terms of their ability to discriminate between troublesome symptoms (TS) and non-troublesome symptoms (NTS). Our objective is to evaluate the ability of the Reflux Disease Questionnaire (RDQ) to identify GERD according to referral of TS, in patients without previous proton pump inhibitor (PPI) treatment and in patients on PPI treatment.

Methods

Patients consulting physicians because of heartburn or acid regurgitation were recruited at 926 primary-care centres in Spain. They were asked to complete several questionnaires including the RDQ, and to define which of their symptoms were troublesome. Information on drug treatment was collected by the physician. We performed a receiver operating characteristic (ROC) curve analysis to ascertain the RDQ's optimum cut-point for identifying TS.

Results

4574 patients were included, 1887 without PPI and 2596 on PPI treatment. Among those without PPI treatment, 1722 reported TS. The area under the curve (AUC) was 0.79 for the RDQ, and the optimum RDQ cut-point for identifying TS was 3.18 (sensitivity, 63.2%; specificity, 80.2%). A total of 2367 patients on PPI treatment reported TS, and the optimum RDQ cut-off value was 3.06 (sensitivity, 65.4%; specificity, 71.8%).

Conclusions

An RDQ score higher than 3 shows good sensitivity and specificity for differentiating TS from NTS among patients without PPI or on PPI treatment. The RDQ is useful in primary care for diagnosis of GERD based on the Montreal definition.

【 授权许可】

   
2014 Rey et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Diaz-Rubio M, Moreno-Elola-Olaso C, Rey E, et al.: Symptoms of gastro-oesophageal reflux: prevalence, severity, duration and associated factors in a Spanish population. Aliment Pharmacol Ther 2004, 19(1):95-105.
• [2]Locke GR III, Talley NJ, Fett SL, et al.: Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997, 112(5):1448-56.
• [3]Rey E, Moreno-Elola-Olaso C, Rodriguez-Artalejo F, et al.: Medical consultation for gastro-oesophageal reflux symptoms: reasons and associated factors. Digestion 2004, 70(3):173-7.
• [4]Bretagne JF, Honnorat C, Richard-Molard B, et al.: Comparative study of characteristics and disease management between subjects with frequent and occasional gastro-oesophageal reflux symptoms. Aliment Pharmacol Ther 2006, 23(5):607-16.
• [5]Vakil N, van Zanten SV, Kahrilas P, et al.: The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006, 101(8):1900-20.
• [6]Wiklund I, Carlsson J, Vakil N: Gastroesophageal reflux symptoms and well-being in a random sample of the general population of a Swedish community. Am J Gastroenterol 2006, 101(1):18-28.
• [7]Wright CE, Ebrecht M, Mitchell R, et al.: The effect of psychological stress on symptom severity and perception in patients with gastro-oesophageal reflux. J Psychosom Res 2005, 59(6):415-24.
• [8]Marzo M, Alonso P, Bonfill X: [Clinical practice guideline on the management of patients with gastroesophageal reflux disease (GERD)]. Gastroenterol Hepatol 2002, 25(2):85-110.
• [9]Armstrong D, Marshall JK, Chiba N, et al.: Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005, 19(1):15-35.
• [10]Bytzer P: Assessment of reflux symptom severity: methodological options and their attributes. Gut 2004, 53(Suppl 4):iv28-iv34.
• [11]McColl E, Junghard O, Wiklund I, et al.: Assessing symptoms in gastroesophageal reflux disease: how well do clinicians' assessments agree with those of their patients? Am J Gastroenterol 2005, 100(1):11-8.
• [12]Fallone CA, Guyatt GH, Armstrong D, et al.: Do physicians correctly assess patient symptom severity in gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2004, 20(10):1161-9.
• [13]Shaw M, Dent J, Beebe T, et al.: The Reflux Disease Questionnaire: a measure for assessment of treatment response in clinical trials. Health Qual Life Outcomes 2008, 6:31. BioMed Central Full Text
• [14]Nuevo J, Tafalla M, Zapardiel J: [Validation of the Reflux Disease Questionnaire (RDQ) and Gastrointestinal Impact Scale (GIS) in patients with gastroesophageal reflux disease in the Spanish population]. Gastroenterol Hepatol 2009, 32(4):264-73.
• [15]Jones R, Coyne K, Wiklund I: The gastro-oesophageal reflux disease impact scale: a patient management tool for primary care. Aliment Pharmacol Ther 2007, 25(12):1451-9.
• [16]Dent J, Vakil N, Jones R, et al.: Accuracy of the diagnosis of GORD by questionnaire, physicians and a trial of proton pump inhibitor treatment: the Diamond Study. Gut 2010, 59(6):714-21.
• [17]Locke GR, Talley NJ, Weaver AL, et al.: A new questionnaire for gastroesophageal reflux disease. Mayo Clin Proc 1994, 69(6):539-47.
• [18]Moreno Elola-Olaso C, Rey E, Rodriguez-Artalejo F, et al.: Adaptation and validation of a gastroesophageal reflux questionnaire for use on a Spanish population. Rev Esp Enferm Dig 2002, 94(12):745-58.
• [19]Jo SY, Kim N, Lim JH, et al.: Comparison of gastroesophageal reflux disease symptom and proton pump inhibitor response using gastroesophageal reflux disease impact scale questionnaire. J Neurogastroenterol Motil 2013, 19:61-69.
• [20]Revicki DA, Wood M, Wiklund I, et al.: Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease. Qual Life Res 1998, 7(1):75-83.
• [21]Kulich KR, Pique JM, Vegazo O: [Psychometric validation of translation to Spanish of the gastrointestinal symptoms rating scale (GSRS) and quality of life in reflux and dyspepsia (QOLRAD) in patients with gastroesophageal reflux disease]. Rev Clin Esp 2005, 205(12):588-94.
• [22]Wiklund IK, Junghard O, Grace E, et al.: Quality of Life in Reflux and Dyspepsia patients. Psychometric documentation of a new disease-specific questionnaire (QOLRAD). Eur J Surg Suppl 1998, 583:41-9.
• [23]Flook N, Jones R, Vakil N: Approach to gastroesophageal reflux disease in primary care: putting the Montreal definition into practice. Can Fam Physician 2008, 54(5):701-5.
• [24]Reimer C, Bytzer P: Perceptions and beliefs concerning gastroesophageal reflux disease: physicians and patients disagree. Digestion 2007, 76(3–4):229-34.
• [25]Bai Y, Du J, Zou D: Gastroesophageal Reflux Disease Questionnaire (GerdQ) in real- world practice: a national multicenter survey on 8065 patients. J Gastroenterol Hepatol 2013. doi:10.1111/jgh.12125 [Epubhead of print])
• [26]Reimer C, Bytzer P: A population-based survey to assess troublesome symptoms in gastroesophageal reflux disease. Scand J Gastroenterol 2009, 44(4):394-400.
• [27]Schey R, Dichman R, Parthasarathy S, et al.: Sleep deprivation hyperalgesic in patienes with gastroesophageal reflux disease. Gastroenterology 2007, 133:1787-1795.
• [28]Jung HK, Choung RS, Talley NJ: Gastroesophageal reflux disease and sleep disorders: evidence for a casual link and therapeutic implications. J Neurogastroenterol Motil 2010, 16:22-29.
• [29]Orr WC, Goodrich S, Fernsröm P, et al.: Occurrence of nighttime gastroesopahgeal reflux in disturbed and normal sleepers. Clin Gastroenterol Hepatol 2008, 6:1099-1104.
• [30]Ponce J, Vegazo O, Beltran B, et al.: Prevalence of gastro-oesophageal reflux disease in Spain and associated factors. Aliment Pharmacol Ther 2006, 23(1):175-84.
• [31]Eslick GD, Talley NJ: Gastroesophageal reflux disease (GERD): risk factors, and impact on quality of life-a population-based study. J Clin Gastroenterol 2009, 43(2):111-7.
• [32]Madalosso CA, Fornari F, Callegari-Jacques SM, et al.: Performance of the Montreal consensus in the diagnosis of gastroesophageal reflux disease in morbidly obese patients. Obes Surg 2008, 18(6):668-74.